4Vote!
Business Wire (Free subscription) | 11/13/2009
BRISTOL, Tenn.--(BUSINESS WIRE)--King Pharmaceuticals, Inc. (NYSE:KG) today announced plans to present at the Lazard Capital Markets 6th Annual Healthcare Conference on Wednesday, November 18, 2009, at 2:15 pm EST, at the St. Regis Hotel in New York, New York. The presentation may include a discussion of the Company’s marketed products, pipeline, strategy for growth, financial results...
4Vote!
Market Watch (Free subscription) | 11/05/2009
NEW YORK (MarketWatch) -- King Pharmaceuticals Inc. said Thursday its third-quarter profit fell to $42 million, or 17 cents a share, from $82 million, or 34 cents a share, in the year-ago period. Total revenues rose 19.3% to $463 million. The Bristol, Tenn.-based pharmaceutical company said adjusted earnings were 29 cents a share. Analysts surveyed by FactSet Research had expected, on...
+Vote!
Business Wire (Free subscription) | 11/05/2009
BRISTOL, Tenn.--(BUSINESS WIRE)--King Pharmaceuticals, Inc. (NYSE:KG) announced today that total revenues were $463 million during the third quarter ended September 30, 2009, compared to $388 million in the third quarter of 2008. The Company reported net income of $42 million and diluted earnings per share of $0.17 during the third quarter of 2009, compared to net income of $82 million...
+Vote!
Business Wire (Free subscription) | 10/29/2009
BRISTOL, Tenn.--(BUSINESS WIRE)--King Pharmaceuticals, Inc. (NYSE:KG) announced today that the Company plans to report financial results for the third quarter ended September 30, 2009 prior to the market open on Thursday, November 5, 2009. The Company also plans to provide a live conference call which may include discussion of the Company’s marketed products, pipeline, financial...
3Vote!
StreetInsider.com News Articles (Free subscription) | 11/19/2009
Notable 52-week Highs on the NYSE: Cardinal Health, Inc. (NYSE: CAH) - Hit $31.77. UBS initiated coverage with a Buy rating on Cardinal. Donaldson Company Inc. (NYSE: DCI) - touched $45.09. The company reported Q110 earnings about the Street estimates today. IMS Health Inc. (NYSE: RX) - reached $21.65 King Pharmaceuticals Inc. (NYSE: KG) - hit $11.88. May be benefitting...
4Vote!
Market Wire (Free subscription) | 11/19/2009
NEW DELHI, INDIA (MARKET WIRE) Wallstsense.com is an online community with a dedicated team of analysts who are providing free in-depth research on North American equities. Our analysts have issued complimentary analysis on the following six companies: Allegheny Technologies Inc. (NYSE: ATI), Gerdau S.A. (NYSE: GGB), King Pharmaceuticals Inc. (NYSE: KG), Agilent Technologies Inc....
4Vote!
Market Wire (Free subscription) | 11/09/2009
NEW DELHI, INDIA (MARKET WIRE) Analyst Choice has combined some of the best financial and technical minds worldwide to bring you an array of free quality equity research and reporting. Today we have begun in-depth reporting on our website evaluating the current market condition of Agilent Technologies Inc. (NYSE: A), Devon Energy Corporation (NYSE: DVN), King Pharmaceuticals Inc....
5Vote!
SeekingAlpha.com (Free subscription) | 11/09/2009
Neil Carvin submits: King Pharmaceuticals, Inc. (NYSE: KG ) earned $0.17 per share in the third quarter of 2009, down from $0.34 in the same quarter of last year. On a non - GAAP (" pro forma " or "ex-items") basis, earnings fell from $0.39 to $0.29 per share. The pretax difference between GAAP and non-GAAP Net Income was $46 million in the latest quarter. The most...
5Vote!
Gauging Corporate Financial Results (Free subscription) | 11/09/2009
King Pharmaceuticals, Inc. ( NYSE: KG ) earned $0.17 per share in the third quarter of 2009, down from $0.34 in the same quarter of last year. On a non - GAAP (" pro forma " or "ex-items") basis, earnings fell from $0.39 to $0.29 per share. The pretax difference between GAAP and non-GAAP Net Income was $46 million in the latest quarter. The most substantial item excluded...
3Vote!
GuruFocus Updates (Free subscription) | 11/13/2009
, the Investment Guru of 2008, made money while others lose. Over the past 12 months, he has seen tremendous growth in the book value of his company, Fairfax Financial Holdings. This is the Q3 portfolio update for Fairfax’s equity portfolio. sells Methanex Corp., King Pharmaceuticals Inc., Alcoa Inc. during the 3-months ended 09/30/2009, according to the most recent filings of...
5Vote!
iStockAnalyst.com (Free subscription) | 11/05/2009
King Pharmaceuticals, Inc. (KG) reported third quarter earnings of 29 cents per share, beating the Zacks Consensus Estimate by 2 cents. Despite revenues increasing 19.3% from the year-ago period, earnings declined 25.6% from the year-ago quarter mainly due to higher operating expenses. [More...]
5Vote!
Seattle Trademark Lawyer (Free subscription) | 11/05/2009
On Nov. 2, King Pharmaceuticals, Inc. , Monarch Pharmaceuticals, Inc., King Pharmaceuticals Research and Development, Inc., and Gentrac, Inc., filed suit against Seattle-based ZymoGenetics, Inc. , in the Eastern District of Tennessee. The complaint alleges a variety of false advertising and trademark infringement claims related to ZymoGenetics’...
4Vote!
Market Wire (Free subscription) | 10/29/2009
LONDON (MARKET WIRE) Benchmark Journal brings independent company and sector research together, utilizing top financial advisors and investment tactics to provide you with a clear picture of investment opportunities. Today we began research on AnnTaylor Stores Corp. (NYSE: ANN), Gerdau S.A. (NYSE: GGB), TRW Automotive Holdings Corp. (NYSE: TRW), Scripps Networks Interactive Inc. (NYSE: SNI),...
